AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9143547 — intervention group
Group type: EXPERIMENTAL
Intervention: Both age groups
Number of subjects: 49
Study 7731897 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent peritoneal dialysis (IPD)
Number of subjects: 8
Study 2489846 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement
Number of subjects: 77
Study 2489846 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 77
Study 2489846 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 77
Study 13937554 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml of 16% antivaccinia gamma-globulin (AGG)
Number of subjects: 106674
Study 13937554 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 106674
Study 31487117 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Cadexomer Iodine for 2 weeks
Number of subjects: 18
Study 31487117 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Cadexomer Iodine for 6 weeks
Number of subjects: 18
Study 31487117 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Cadexomer Iodine (both durations)
Number of subjects: 18
Study 29244829 — intervention group
Group type: EXPERIMENTAL
Intervention: mRDTs and ACTs
Number of subjects: 0
Study 29244829 — intervention group
Group type: COMPARATOR
Intervention: Presumptive diagnosis with ACTs
Number of subjects: 0
Study 26123832 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal maternal ADHD treatment (group psychotherapy plus open methylphenidate medication; treatment group (TG): n = 77)
Number of subjects: 144
Study 26123832 — intervention group
Group type: COMPARATOR
Intervention: Clinical management (supportive counseling without psychotherapy or psychopharmacotherapy; control group (CG): n = 67)
Number of subjects: 144
Study 26123832 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TG and CG)
Number of subjects: 144
Study 23453480 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 330
Study 23453480 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 330
Study 22117992 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cuff pressure regulator
Number of subjects: 60
Study 22117992 — intervention group
Group type: COMPARATOR
Intervention: Standard cuff pressure management (without regulator)
Number of subjects: 60
Study 19185670 — intervention group
Group type: EXPERIMENTAL
Intervention: 24/4 regimen of 20 mcg ethinyl estradiol and 1 mg norethindrone acetate
Number of subjects: 41
Study 19185670 — intervention group
Group type: COMPARATOR
Intervention: 21/7 regimen of 20 mcg ethinyl estradiol and 1 mg norethindrone acetate
Number of subjects: 41
Study 17084909 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) treatment
Number of subjects: 0
Study 17084909 — intervention group
Group type: COMPARATOR
Intervention: Untreated MS patients
Number of subjects: 0
Study 14984147 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue graft with superficial surface facing the gingival flap
Number of subjects: 13
Study 14984147 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft with superficial surface facing the root surface
Number of subjects: 13
Study 11382795 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 lux bright light treatment (1 week, 5 days, 30 minutes daily)
Number of subjects: 10
Study 11382795 — intervention group
Group type: COMPARATOR
Intervention: Placebo (300 lux, 1 week, 5 days, 30 minutes daily)
Number of subjects: 10
Study 11382795 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment, 1 week, 5 days, 30 minutes daily)
Number of subjects: 10
Study 9159562 — intervention group
Group type: COMPARATOR
Intervention: digoxin 0.25 mg day(‐1) + placebo (D + P)
Number of subjects: 12
Study 9159562 — intervention group
Group type: EXPERIMENTAL
Intervention: imidapril 10 mg day(‐1) + digoxin 0.25 mg day(‐1) (I + D)
Number of subjects: 12
Study 9159562 — intervention group
Group type: COMPARATOR
Intervention: imidapril 10 mg day(‐1) + placebo (I + P)
Number of subjects: 12
Study 7958160 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking during pregnancy
Number of subjects: 712
Study 7958160 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking during pregnancy
Number of subjects: 712
Study 3105566 — intervention group
Group type: EXPERIMENTAL
Intervention: Anexate (Ro 15‐1788) 0.36 +/- 0.09 mg
Number of subjects: 65
Study 3105566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 31973706 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pelvic floor muscle exercise (PFME)
Number of subjects: 70
Study 31973706 — intervention group
Group type: COMPARATOR
Intervention: Postoperative period PFME (group B)
Number of subjects: 70
Study 29455722 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMI-teen pregnancy prevention
Number of subjects: 945
Study 29455722 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMI-Fitness
Number of subjects: 945
Study 26924204 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and antismoking advice
Number of subjects: 1232
Study 26924204 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1232
Study 26702639 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week online spirituality informed e-mental health intervention (the LEAP Project)
Number of subjects: 62
Study 26702639 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control arm (intervention initiated after an 8-week wait period)
Number of subjects: 62
Study 23796685 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle energy technique (MET)
Number of subjects: 82
Study 23796685 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection (CSI)
Number of subjects: 82
Study 20306354 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative therapy (8 sessions)
Number of subjects: 47
Study 17947224 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant TAM
Number of subjects: 1096
Study 17947224 — intervention group
Group type: COMPARATOR
Intervention: Sequential TAM
Number of subjects: 1096
Study 16480553 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined planning intervention (action planning and coping planning)
Number of subjects: 211
Study 16480553 — intervention group
Group type: COMPARATOR
Intervention: Action planning alone
Number of subjects: 211
Study 16480553 — intervention group
Group type: COMPARATOR
Intervention: Standard-care control group
Number of subjects: 211
Study 12923684 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen phonophoresis (PH)
Number of subjects: 60
Study 12923684 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound (US)
Number of subjects: 60
Study 11127170 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive smoking cessation programme in routine primary care (n = 1203)
Number of subjects: 1768
Study 11127170 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 565)
Number of subjects: 1768
Study 8836986 — intervention group
Group type: COMPARATOR
Intervention: L-DOPA
Number of subjects: 0
Study 8836986 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA + L-threo-DOPS
Number of subjects: 0
Study 8836986 — intervention group
Group type: EXPERIMENTAL
Intervention: L-threo-DOPS
Number of subjects: 0
Study 1624009 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot
Number of subjects: 0
Study 1624009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6439648 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (150,000 IU/week)
Number of subjects: 103
Study 6439648 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (180 mg/week in 6 capsules)
Number of subjects: 103
Study 6439648 — intervention group
Group type: COMPARATOR
Intervention: Canthaxanthin (180 mg/week in 6 capsules)
Number of subjects: 103
Study 6439648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 31564448 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese opera (12 weeks)
Number of subjects: 43
Study 31802880 — intervention group
Group type: EXPERIMENTAL
Intervention: PNNS+ (adherence to the French Nutrition and Health Program guidelines, n=26)
Number of subjects: 49
Study 31802880 — intervention group
Group type: COMPARATOR
Intervention: PNNS- (non-adherence to the French Nutrition and Health Program guidelines, n=23)
Number of subjects: 49
Study 28225186 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of oltipraz twice daily for 24 weeks
Number of subjects: 68
Study 28225186 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of oltipraz twice daily for 24 weeks
Number of subjects: 68
Study 28225186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 25909599 — intervention group
Group type: EXPERIMENTAL
Intervention: Total colonic decompression
Number of subjects: 300
Study 25909599 — intervention group
Group type: COMPARATOR
Intervention: Control group (no decompression)
Number of subjects: 300
Study 24707145 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day regimen of amoxicillin 1 g, clarithromycin 500 mg, and rabeprazole 20 mg twice daily
Number of subjects: 50
Study 24707145 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day regimen of amoxicillin 1 g, clarithromycin 500 mg, and rabeprazole 20 mg twice daily
Number of subjects: 50
Study 22435793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial pressure (ICP) monitoring
Number of subjects: 176
Study 22435793 — intervention group
Group type: COMPARATOR
Intervention: No ICP monitoring (Control)
Number of subjects: 176
Study 19567799 — intervention group
Group type: EXPERIMENTAL
Intervention: Laptop computer
Number of subjects: 160
Study 19567799 — intervention group
Group type: COMPARATOR
Intervention: Handheld computer
Number of subjects: 160
Study 17935545 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of lovastatin plus 10 g of psyllium
Number of subjects: 36
Study 17935545 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of lovastatin
Number of subjects: 36
Study 17935545 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of psyllium
Number of subjects: 36
Study 15465203 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) followed by conventional external beam radiation therapy (EBRT) with carmustine (BCNU)
Number of subjects: 203
Study 15465203 — intervention group
Group type: COMPARATOR
Intervention: Conventional external beam radiation therapy (EBRT) with carmustine (BCNU) alone
Number of subjects: 203
Study 15465203 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) followed by EBRT with BCNU
Number of subjects: 203
Study 11755954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancrod (1.0, 1.5, and 2.0 IU/kg body weight)
Number of subjects: 32
Study 11755954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 10036657 — intervention group
Group type: EXPERIMENTAL
Intervention: UCLP group
Number of subjects: 143
Study 10036657 — intervention group
Group type: COMPARATOR
Intervention: NCC group
Number of subjects: 143
Study 7748845 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour modification programme including dental examinations, visits by dental hygienists, and contracts with children and parents
Number of subjects: 16
Study 7748845 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what intervention was provided)
Number of subjects: 16
Study 2899496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime and metronidazole (75 mg/kg and 10 mg/kg intravenously in 3 doses at 12-hourly intervals) administered preoperatively or perioperatively (group 1)
Number of subjects: 401
Study 2899496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime and metronidazole (75 mg/kg and 10 mg/kg intravenously in 3 doses at 12-hourly intervals) plus peritoneal lavage with cefotaxime 2 g/L during surgery (group 2)
Number of subjects: 401
Study 2899496 — intervention group
Group type: COMPARATOR
Intervention: Non-lavage group (group 1)
Number of subjects: 401
Study 2899496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavage group (group 2)
Number of subjects: 401
Study 2899496 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 401
Study 31141634 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 881
Study 31141634 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 881
Study 28552790 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training (EMST)
Number of subjects: 25
Study 25466655 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine 30 g/d (10 g powder, three times a day)
Number of subjects: 66
Study 25466655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 23073982 — intervention group
Group type: EXPERIMENTAL
Intervention: ZAP questionnaire (modified version)
Number of subjects: 1773
Study 21929769 — intervention group
Group type: EXPERIMENTAL
Intervention: iCPR tool
Number of subjects: 149
Study 21929769 — intervention group
Group type: COMPARATOR
Intervention: Control (simulated group)
Number of subjects: 149
Study 18060377 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance-enhancing program in patients with statin therapy
Number of subjects: 7640
Study 16836480 — intervention group
Group type: COMPARATOR
Intervention: Positive information about one novel animal; Negative information about another novel animal; No information about a third animal.
Number of subjects: 0
Study 16836480 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial dot-probe task (immediate and 24-hr delay)
Number of subjects: 0
Study 14656779 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg*kg(‐1)
Number of subjects: 40
Study 14656779 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.2 mg*kg(‐1)
Number of subjects: 40
Study 14656779 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study 10738435 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic beads
Number of subjects: 67
Study 10738435 — intervention group
Group type: COMPARATOR
Intervention: Conventional intravenous antibiotics
Number of subjects: 67
Study 10738435 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic beads and intravenous antibiotics (nonrandomized third cohort)
Number of subjects: 67
Study 9183501 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol expectancy
Number of subjects: 64
Study 9183501 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 64
Study 9183501 — intervention group
Group type: COMPARATOR
Intervention: Expectancy of alcohol (in males)
Number of subjects: 64
Study 1279634 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (1.5 pmol/kg-1/min-1 over 60 min)
Number of subjects: 14
Study 1279634 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 14
Study 1279634 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (0.5 pmol/kg-1/min-1 over 60 min)
Number of subjects: 14
Study 1279634 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (1 pmol/kg-1/min-1 over 60 min)
Number of subjects: 14
Study 1279634 — intervention group
Group type: COMPARATOR
Intervention: GH-RH (1 micrograms/kg body weight in an IV bolus) during saline infusion
Number of subjects: 14
Study 1279634 — intervention group
Group type: EXPERIMENTAL
Intervention: GH-RH (1 micrograms/kg body weight in an IV bolus) during SP infusion
Number of subjects: 14
Study 2987294 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (glucocorticoid therapy)
Number of subjects: 14
Study 30669640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mountain hiking in an environment with less anthropogenic elements
Number of subjects: 52
Study 30669640 — intervention group
Group type: COMPARATOR
Intervention: Mountain hiking in an environment with more anthropogenic elements
Number of subjects: 52
Study 30669640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mountain hiking (both conditions)
Number of subjects: 52
Study 30217229 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic and selenium co-supplementation (8×10^9 CFU/day probiotic plus 200 μg/day selenium)
Number of subjects: 60
Study 26946962 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 232
Study 26946962 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs11649514 in PRKCB
Number of subjects: 232
Study 25338248 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage by acupressure
Number of subjects: 45
Study 25338248 — intervention group
Group type: COMPARATOR
Intervention: Garlium Arseneid Laser 904 nm turned off (placebo)
Number of subjects: 45
Study 25338248 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 45
Study 21777283 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 693
Study 21777283 — intervention group
Group type: COMPARATOR
Intervention: Magnifying chromoendoscopy (MCE)
Number of subjects: 693
Study 20191831 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen section exam
Number of subjects: 0
Study 20191831 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy technique
Number of subjects: 0
Study 20191831 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 0
Study 17275150 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Number of subjects: 19
Study 14665500 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 to 400 mg qd)
Number of subjects: 125
Study 11009043 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (13.5 + 13.5 + 27 microg)
Number of subjects: 23
Study 11009043 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (300 + 300 + 600 microg)
Number of subjects: 23
Study 11009043 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (9 microg twice daily)
Number of subjects: 23
Study 11009043 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (900 + 900 + 1800 microg)
Number of subjects: 23
Study 11009043 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no treatment)
Number of subjects: 23
Study 10451943 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH (fraxiparin) 60 anti Xa IU.kg‐1.day‐1 plus steroid, cyclophosphamide, and bennazipril
Number of subjects: 41
Study 10451943 — intervention group
Group type: COMPARATOR
Intervention: Control group (steroid, cyclophosphamide, and bennazipril)
Number of subjects: 41
Study 1589566 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (20 mg)
Number of subjects: 50
Study 1589566 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 50
Study 1589566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2423333 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg IV followed by 100 mg twice daily for 15 days)
Number of subjects: 126
Study 2423333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 31517823 — intervention group
Group type: EXPERIMENTAL
Intervention: Dangguijakyaksan
Number of subjects: 46
Study 31517823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 29417761 — intervention group
Group type: EXPERIMENTAL
Intervention: M923 (40 mg)
Number of subjects: 315
Study 29417761 — intervention group
Group type: COMPARATOR
Intervention: US Humira
Number of subjects: 315
Study 29417761 — intervention group
Group type: COMPARATOR
Intervention: EU Humira
Number of subjects: 315
Study 29417761 — intervention group
Group type: EXPERIMENTAL
Intervention: M923
Number of subjects: 315
Study 27468258 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAAs and CHO (3 g/d L-leucine, 1 g/d L-isoleucine, 2 g/d L-valine with 2 g of CHO; n=15)
Number of subjects: 30
Study 27468258 — intervention group
Group type: COMPARATOR
Intervention: CHO only (42 g of CHO; n=15)
Number of subjects: 30
Study 27468258 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAAs and CHO
Number of subjects: 30
Study 27468258 — intervention group
Group type: COMPARATOR
Intervention: CHO only
Number of subjects: 30
Study 25372381 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (30 min on a treadmill at ventilatory threshold intensity)
Number of subjects: 9
Study 25372381 — intervention group
Group type: COMPARATOR
Intervention: Control (seated for 150 min)
Number of subjects: 9
Study 22961772 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent affect
Number of subjects: 0
Study 22961772 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat affect
Number of subjects: 0
Study 22961772 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective deviants (targets with non-normative reactions)
Number of subjects: 0
Study 22961772 — intervention group
Group type: COMPARATOR
Intervention: Normative reactions (control group)
Number of subjects: 0
Study 20645530 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab 22.5 or 45 mg/kg s.c. (n = 32)
Number of subjects: 54
Study 20645530 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab 0.09-4.5 mg/kg i.v. or 0.27-2.7 mg/kg s.c. (n = 46)
Number of subjects: 54
Study 20645530 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab (n = 20)
Number of subjects: 54
Study 18393008 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal perception of fetal movements
Number of subjects: 0
Study 18393008 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal fetal movement counting
Number of subjects: 0
Study 18393008 — intervention group
Group type: EXPERIMENTAL
Intervention: Defined limits for reduced fetal movements in a low risk population
Number of subjects: 0
Study 16288390 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MXF) 400 mg once daily intravenously, possibly followed by oral tablets
Number of subjects: 397
Study 16288390 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (CTRX) 2 g intravenously once daily with or without Erythromycin (ERY) 1 g intravenously every 6-8 h
Number of subjects: 397
Study 16288390 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MXF)
Number of subjects: 397
Study 16288390 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (CTRX) with or without Erythromycin (ERY)
Number of subjects: 397
Study 12855386 — intervention group
Group type: EXPERIMENTAL
Intervention: Version 1 (attributed lower forecast income of women to intrinsic gender factors)
Number of subjects: 100